Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -77.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $609891 | $532172 | $650541 | $915569 | $2M | $4M | $2M | $2M | $1M | — | — |
| Enterprise Value | $-215830 | $-293549 | $-2851280 | $-2520587 | $-8204267 | $-10832540 | $2M | $2M | $997434 | — | — |
| P/E Ratio → | -0.15 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.20 | 0.26 | 0.14 | 0.20 | 0.31 | 0.31 | 1.44 | — | 3.78 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.2% | -77.2% | -96.2% | -49.1% | -69.2% | -22.9% | -246.0% | -1146.6% | -1174.3% | — | — |
| ROA | -62.0% | -62.0% | -79.9% | -32.1% | -47.0% | -16.8% | -76.0% | -53.5% | -430.1% | -122.7% | -170.7% |
| ROIC | -191.4% | -191.4% | -338.2% | — | — | — | -187.6% | — | — | — | — |
| ROCE | -94.7% | -94.7% | -113.2% | -59.9% | -89.8% | -32.1% | -207.2% | -739.5% | -293.1% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — | 0.13 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -0.73 | -0.74 | -1.48 | -1.13 | -0.14 | — | -0.67 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 2.68 | — |
| Interest Coverage | — | — | — | — | — | -665.28 | -94.07 | -15.92 | -48.82 | -28.71 | -47.00 |
Net cash position: cash ($862940) exceeds total debt ($37219)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.61 | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 | 1.99 | 0.48 | 1.09 | 0.06 | 0.03 |
| Quick Ratio | 1.61 | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 | 2.00 | 0.35 | 1.09 | 0.06 | 0.03 |
| Cash Ratio | 1.44 | 1.44 | 3.26 | 11.69 | 6.90 | 26.74 | 0.17 | 0.05 | 0.29 | 0.06 | 0.23 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | 0.12 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $189385 | $115140 | $79270 | $59195 | $43765 | $29620 | $25035 | $25035 | $8505 | $7135 |
Imminent liquidity and dilution
Based on reported figures, XRTX trades at a P/B ratio of 0.20, which suggests that the market is heavily discounting the company's book value due to the extreme uncertainty surrounding its clinical-stage pipeline and the lack of any current commercial revenue streams to support valuation.
The low P/B multiple reflects a market that is pricing in significant dilution risk rather than the potential upside of the XRx-008 program. Investors should note that traditional valuation metrics like P/E are non-meaningful here, as the company remains in a pre-revenue, high-burn phase where equity value is tied entirely to future regulatory milestones.
According to recent financial statements, XRTX's ROIC has trended deeply negative, reaching -52.8% in 2026Q1, which indicates that the company is currently destroying shareholder capital as it funds clinical development without generating any offsetting operational returns or commercial product revenue.
The consistent decay in return metrics highlights the structural challenge of funding long-term R&D through equity markets. This trend suggests that management's current capital allocation is not yet yielding the efficiency required to create value, necessitating a successful clinical readout to reverse the downward trajectory of capital returns.
As reported in 2026Q1 filings, the company's current ratio has deteriorated to 0.43, a sharp decline from the 13.80 level observed in 2023Q4, signaling that current assets are increasingly insufficient to cover short-term liabilities as the cash runway reaches a precarious state.
This liquidity contraction implies that the company may face an imminent need for external financing to maintain its clinical trial operations. Investors should monitor the company's ability to secure non-dilutive funding, as the current balance sheet position leaves little room for operational delays or unexpected cost overruns.
The P/B ratio is frequently misapplied to XRTX, as it obscures the reality that the company's book value is largely composed of cash and intangible assets that are rapidly being depleted to fund clinical trials rather than being used for productive, revenue-generating operations.
Instead of relying on book value, analysts should focus on the cash-to-burn ratio to assess the company's true operational viability. Using P/B in this context may lead to a false sense of security regarding the company's asset backing, when in reality, the firm's survival is entirely dependent on its ability to raise capital.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying XRTX stock.
XORTX Therapeutics Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
XORTX Therapeutics Inc.'s return on equity (ROE) is -77.2%. The historical average is -98.7%.
Based on historical data, XORTX Therapeutics Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.